CC BY-NC-ND 4.0 · Laryngorhinootologie 2021; 100(S 02): S113-S114
DOI: 10.1055/s-0041-1727934
Abstracts
Head-Neck-Oncology: Clinical Studies

Treatment according to the DeLOS-II protocol shows survival benefit of patients with locoregional advanced larynx and hypopharynx cancer

T Wald
1   Universitätsklinikum Leipzig, Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde/Plastische Chirurgie, Leipzig
,
G Wichmann
1   Universitätsklinikum Leipzig, Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde/Plastische Chirurgie, Leipzig
,
V Zebralla
1   Universitätsklinikum Leipzig, Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde/Plastische Chirurgie, Leipzig
,
A Dietz
1   Universitätsklinikum Leipzig, Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde/Plastische Chirurgie, Leipzig
,
S Wiegand
1   Universitätsklinikum Leipzig, Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde/Plastische Chirurgie, Leipzig
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction Larynx organ preservation (LOP) in locoregional advanced laryngeal and hypopharyngeal squamous cell carcinoma (LHSCC) that can only be surgically treated by total laryngectomy (TL) may be achieved via cisplatin-based concurrent radio-chemotherapy (CRT) or induction-chemotherapy followed by radiotherapy (IC+RT). RTOG 91-11 and other randomized controlled trials (RCT) suggest superior tumor-specific and overall survival after CRT compared to IC+RT but inferior survival of T4a LHSCC compared to TL followed by postoperative RT (TL+PORT) or radio-chemotherapy (TL+PORCT). As head-to-head comparisons in RCT of the 4 alternatives are missing, we aimed on a reliable comparison of outcome data from LHSCC patients treated in our hospital in the DeLOS-II LOP trial and risk factor-matched LHSCC patients treated according to NCCN guideline utilizing CRT, TL+PORT and TL+PORCT.

    Patients and methods The LOP trial DeLOS-II used endoscopic tumor staging after 1 cycle IC for selecting TL+POR(C)T for non-responders vs. IC+RT for responders. Main risk factors for survival (localization hypopharynx, T4a, N+, history of high level tobacco smoking and alcohol consumption, age, male sex) were used to match each DeLOS-II patient to one patient each undergoing CRT, TL+PORT and TL+PORCT out of 445 LHSCC patients treated at our hospital until 2016.

    Results The 52 DeLOS-II patients and 3 matched cohorts (52 LHSCC patients each) had equal distribution regarding risk factors but differed in outcome. The 52 DeLOS-II patients had significantly improved survival, especially tumor-specific survival.

    Conclusions Patients with locally advanced LHSCC benefit from applying the DeLOS-II protocol, probably because of the early and efficient patient selection after short induction-chemotherapy.

    Poster-PDF A-1158.pdf


    #

    Conflict of interest

    Der Erstautor gibt keinen Interessenskonflikt an.

    Address for correspondence

    Wald Theresa
    Universitätsklinikum Leipzig, Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde/Plastische Chirurgie
    Leipzig

    Publication History

    Article published online:
    13 May 2021

    © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany